Loading...
XSHE300181
Market cap1.40bUSD
Jan 15, Last price  
14.94CNY
1D
-0.60%
1Q
-3.61%
Jan 2017
63.64%
IPO
268.41%
Name

Zhejiang Jolly Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300181 chart
P/E
26.78
P/S
5.28
EPS
0.56
Div Yield, %
2.14%
Shrs. gr., 5y
2.73%
Rev. gr., 5y
21.61%
Revenues
1.94b
+7.61%
126,585,142164,902,489215,349,830262,655,252279,327,509343,758,925419,415,230514,926,219670,857,129840,037,943793,911,691730,262,647911,163,9751,090,878,1691,457,396,0661,805,155,3651,942,492,990
Net income
383m
+40.27%
13,894,15316,642,66031,584,33841,476,73050,927,86662,002,51380,997,527103,184,20384,772,99172,020,42545,140,28220,751,76925,592,84288,801,777179,408,091273,006,652382,936,093
CFO
288m
-9.46%
16,047,61331,157,75743,892,65664,780,15013,654,67230,509,25729,503,76713,695,17097,128,28958,304,4566,506,36478,284,593128,942,614279,691,036251,798,511318,591,105288,461,038
Dividend
May 22, 20240.45 CNY/sh
Earnings
May 09, 2025

Profile

Zhejiang Jolly Pharmaceutical Co., Ltd. engages in the research, production, and marketing of Chinese medicinal products in China and internationally. The company offers Wuling capsule that is used to treat insomnia, amnesia, heart palpitations, lack of energy, lassitude in loin and legs, and giddy tinnitus, as well as deficiency of energy and weak pulse caused by the disharmony of heart and kidney, or neurasthenia. It also provides Lingze tablet, which is used to treat frequent urination, dysuria, weak steam of urine, endless urine, and soreness and weakness of waist and knees caused by benign prostatic hyperplasia, kidney deficiency, and blood stasis; and Bailing tablet that is used as the adjuvant therapy to treat cough, asthma, back pain, and chronic bronchitis, which are caused by the deficiency of lungs and kidney. In addition, the company offers Linglianhua particles for the treatment of symptoms, including sweating, insomnia, dysphoria, heart palpitations, dreaminess, giddy tinnitus, lassitude in loin and legs, dry stool, and abnormal furred tongue, as well as weak pulse caused by perimenopausal syndrome, or disharmony of heart and kidney. Further, it provides azithromycin, clindamycin phosphate, doxapram, pefloxacin mesylate, adenosine cyclophosphate, and sodium nitroprusside injections. Additionally, the company offers materials, such as cordyceps cephalosporium, fermented cordyceps, and Wuling powders. It also invests and participates in the medical services of Deqing No.3 People's Hospital. The company was formerly known as Zhejiang Jolly Pharmaceutical Health Products Co., LTD. and changed its name to Zhejiang Jolly Pharmaceutical Co., Ltd. in 1998. Zhejiang Jolly Pharmaceutical Co., Ltd. was founded in 2000 and is based in Huzhou, China.
IPO date
Feb 22, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,942,493
7.61%
1,805,155
23.86%
Cost of revenue
1,433,726
1,464,376
Unusual Expense (Income)
NOPBT
508,767
340,780
NOPBT Margin
26.19%
18.88%
Operating Taxes
55,879
38,603
Tax Rate
10.98%
11.33%
NOPAT
452,889
302,177
Net income
382,936
40.27%
273,007
52.17%
Dividends
(219,955)
(121,725)
Dividend yield
2.96%
1.63%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
193,061
140,998
Long-term debt
33,375
54,262
Deferred revenue
19,897
19,757
Other long-term liabilities
1
Net debt
(885,243)
(1,279,174)
Cash flow
Cash from operating activities
288,461
318,591
CAPEX
(131,715)
Cash from investing activities
(263,576)
Cash from financing activities
(159,320)
643,099
FCF
180,134
125,066
Balance
Cash
1,082,979
1,092,899
Long term investments
28,700
381,535
Excess cash
1,014,555
1,384,176
Stockholders' equity
1,480,842
1,632,156
Invested Capital
1,989,038
1,508,314
ROIC
25.90%
21.05%
ROCE
16.82%
11.49%
EV
Common stock shares outstanding
696,247
701,387
Price
10.66
-0.09%
10.67
-8.49%
Market cap
7,421,998
-0.83%
7,483,803
5.46%
EV
6,581,959
6,260,805
EBITDA
573,688
401,288
EV/EBITDA
11.47
15.60
Interest
7,623
8,320
Interest/NOPBT
1.50%
2.44%